Also trades as: 2616.HK (HKSE) · $vol 8M
CSPHF OTC
CStone Pharmaceuticals
1W: +4.9%
1M: +10.4%
3M: +26.9%
YTD: -15.4%
1Y: -24.5%
3Y: +51.0%
5Y: -32.0%
$0.76
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$263M
-35.5% ▼
5Y CAGR: -24.0%
Gross Profit
$45M
-81.4% ▼
5Y CAGR: -43.8%
Operating Income
-$421M
-359.6% ▼
Net Income
-$426M
-366.8% ▼
EPS (Diluted)
$-0.31
-333.6% ▼
EBITDA
-$379M
-1343.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $244M | $481M | $464M | $407M | $263M |
| YoY Growth | -76.5% | +97.5% | -3.6% | -12.2% | -35.5% |
| Cost of Revenue | $107M | $203M | $160M | $167M | $218M |
| Gross Profit | $137M | $278M | $304M | $240M | $45M |
| Gross Margin | 56.2% | 57.8% | 65.6% | 59.0% | 17.1% |
| R&D Expenses | $1.3B | $614M | $528M | $135M | $303M |
| SG&A Expenses | $473M | $390M | $248M | $167M | $163M |
| Operating Expenses | $2.0B | $1.2B | $884M | $332M | $466M |
| Operating Income | -$1.8B | -$912M | -$580M | -$92M | -$421M |
| Operating Margin | -750.6% | -189.5% | -125.0% | -22.5% | -160.5% |
| Interest Expense | $2M | $8M | $12M | $15M | $13M |
| Income Before Tax | -$1.9B | -$903M | -$367M | -$91M | -$413M |
| Tax Expense | $0 | $0 | $0 | $0 | $13M |
| Net Income | -$1.9B | -$903M | -$367M | -$91M | -$426M |
| Net Margin | -787.8% | -187.5% | -79.2% | -22.4% | -162.1% |
| EPS (Diluted) | $-1.65 | $-0.77 | $-0.29 | $-0.07 | $-0.31 |
| EBITDA | -$1.9B | -$850M | -$297M | -$26M | -$379M |
| Shares Outstanding | 1.17B | 1.17B | 1.26B | 1.28B | 1.39B |